At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 target
Drug / intervention
Amodiaquine +1 moredrug
Likely dose
Amodiaquine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Longitudinal Study of Interactions Between HIV and Malaria in Ugandan Children: A UCSF/Makerere University "Children With HIV and Malaria Project"
National Institute of Allergy and Infectious Diseases (NIAID)·observational·Posted Jul 26, 2006·Updated Nov 1, 2021
In Brief
An observational study evaluating Amodiaquine and Artesunate for HIV Infections and Malaria. Completed, enrolled 300 participants across 1 site.
Detailed Summary
HIV and malaria are two of the most important diseases to afflict children in sub-Saharan Africa. However, it is unknown what relationships exist between the two diseases. The purpose of this study is to determine the relationship between HIV and malaria infections in HIV infected Ugandan children.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Malaria
CountriesUganda
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedJul 2006
Primary CompletionApr 2007
Study CompletionMay 2010
TodayJul 2026
First PostedJul 26, 2006
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2007
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.9 years ago
Interventions
Amodiaquinedrug
200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
Artesunatedrug
50 mg oral tablet taken daily for 3 days under direct supervision at study clinic